$DYAI

Dyadic International said it developed stable C1 cell line pools and produced two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens from plasmids in about 15 days. The antigens were delivered to Fondazione Biotecnopolo di Siena and Scripps Research for preclinical evaluation for a potential non-mRNA vaccine. Dyadic also cited prior C1 antibody titers above 12 g/L in seven days.

Dyadic International Inc. (DYAI) said it has regained compliance with Nasdaq Capital Market listing rules after a prior Nasdaq notice citing violations of Rules 5550(a)(2) and 5550(b). According to the latest Nasdaq notification, its common stock will continue trading on Nasdaq. DYAI closed Friday at $1.19, down 1.65%.

Francisco Trust under agreement dated February 28, 1996 sold 95,392 shares of DYADIC INTERNATIONAL INC (DYAI) at an average of $1.31 ($1.21–$1.33, $0.12M total) across 3 trades over 2026-07-22 to 2026-07-24.

Dyadic International, Inc. (Nasdaq: DYAI) said Nasdaq confirmed it has regained compliance with listing rules 5550(a)(2) and 5550(b). The company’s common stock will continue trading on the Nasdaq Capital Market. Dyadic attributed the resolution to Nasdaq’s continued listing review and said it will focus on its protein platforms and collaborations.

Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.

Dyadic International (Nasdaq: DYAI) said it is expanding its bio-industrial pipeline with a new proprietary industrial enzyme program for advanced cellulose processing. The initiative follows commercialization of its EN3ZYME enzyme and uses Dyadic’s Dapibus platform, aiming to streamline development and manufacturing. The company plans optimization, pilot production, and customer evaluations.

Dyadic International (Nasdaq: DYAI) said its C1 microbial protein platform is progressing in multiple funded collaborations. It received the full $3.1M Gates Foundation grant for RSV and malaria mAb work, with a final $738,743 payment in June 2026. CEPI/FBS/Dyadic reported plasmid-to-purified protein in ~15 days; Scripps Ebola work targets initial antigen samples by end-July 2026.

Francisco Trust under agreement dated February 28, 1996 sold 172,864 shares of DYADIC INTERNATIONAL INC (DYAI) at an average of $1.99 ($1.80–$2.43, $0.34M total) across 7 trades over 2024-06-06 to 2025-01-07.

DYADIC INTERNATIONAL INC (DYAI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001213809 0001213809 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Dyadic International (Nasdaq: DYAI) said interest in its C1 protein production platform is rising as global Ebola preparedness efforts continue. The company cited its ability to move from a codon-optimized viral gene to purified antigen or monoclonal antibody in about 15 days and pointed to collaborations and CEPI Ebola funding proposals. Dyadic also highlighted ongoing commercial adoption across life sciences, food, and industrial markets.